retatrutide side effects clinical trials 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide side effects: what the

Endocrinology (2011) 152:310312

Note: Intramuscular dosing is typically between 200-600mg per dose and is sometimes used as long term treatment after initial IV therapy

doi: 10.4103/1673-5374.374139 110

Sleep improvements are typically the first thing patients at our Miami clinic report, often beginning within the first few nights of the cycle

The ideal candidate is generally an adult with a body mass index (BMI) of 27 or higher, with at least one weight-related health issue, or a BMI of 30 or greater without any additional health conditions

The next few years will determine whether this hope translates into real help for patients and families